Phase I trial of vemurafenib and low-dose decitabine in patients with malignant melanoma

Trial Profile

Phase I trial of vemurafenib and low-dose decitabine in patients with malignant melanoma

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2015

At a glance

  • Drugs Decitabine (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2015 New trial record
    • 02 Jun 2015 Due to the response rate in patients receiving vemurafenib + decitabine in a phase I/II trial (see trial profile 700233849), this phase I trial is planned to investigate the effect of decitabine given at a low dose for a longer duration to ensure maximal depletion of DNA methyltransferase, according to an ASCO abstract.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top